Your browser version may not work well with NCBI's Web applications. More information here...
1: Science. 1997 Aug 8;277(5327):815-8.Click here to read Links
Comment in:
Science. 1997 Aug 8;277(5327):768.

An antagonist decoy receptor and a death domain-containing receptor for TRAIL.

Pan G, Ni J, Wei YF, Yu G, Gentz R, Dixit VM.

Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.

TRAIL, also called Apo2L, is a cytotoxic protein that induces apoptosis of many transformed cell lines but not of normal tissues, even though its death domain-containing receptor, DR4, is expressed on both cell types. An antagonist decoy receptor (designated as TRID for TRAIL receptor without an intracellular domain) that may explain the resistant phenotype of normal tissues was identified. TRID is a distinct gene product with an extracellular TRAIL-binding domain and a transmembrane domain but no intracellular signaling domain. TRID transcripts were detected in many normal human tissues but not in most cancer cell lines examined. Ectopic expression of TRID protected mammalian cells from TRAIL-induced apoptosis, which is consistent with a protective role. Another death domain-containing receptor for TRAIL (designated as death receptor-5), which preferentially engaged a FLICE (caspase-8)-related death protease, was also identified.

PMID: 9242610 [PubMed - indexed for MEDLINE]